Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

OR52L1 Inhibitors

OR52L1 inhibitors belong to a class of chemical compounds that specifically target and inhibit the activity of the olfactory receptor 52L1 (OR52L1). Olfactory receptors, such as OR52L1, are G-protein-coupled receptors (GPCRs) primarily known for their role in the detection of odorants. These receptors are part of a large gene family, with hundreds of distinct olfactory receptors that interact with various chemical compounds, contributing to the sense of smell. OR52L1 is one such receptor, and although traditionally associated with olfaction, it is now known to be expressed in tissues outside the nasal epithelium, which suggests it may play additional biological roles. Inhibitors of OR52L1 act by binding to the receptor and blocking its ability to interact with its ligands, thereby modulating signaling pathways activated by this receptor. The design and study of OR52L1 inhibitors are often focused on elucidating the molecular mechanisms of receptor-ligand interactions and understanding the broader physiological functions that the receptor may mediate.

From a chemical perspective, OR52L1 inhibitors can vary widely in their structural properties. Many of these inhibitors are small molecules that are designed or discovered through high-throughput screening techniques or rational drug design. Structural studies often explore the active sites or binding domains of OR52L1 to understand how inhibitors interact with specific amino acid residues within the receptor. The inhibitors can be classified based on their chemical scaffolds, which may include heterocyclic compounds, aromatic rings, or aliphatic chains with functional groups that enhance receptor affinity. Inhibitors can be competitive or non-competitive, depending on how they interfere with ligand binding or signal transduction. Characterizing these inhibitors involves the use of advanced biochemical techniques such as molecular docking, mutagenesis studies, and receptor binding assays. These research efforts provide valuable insights into the structural and functional dynamics of OR52L1, contributing to our broader understanding of GPCR regulation and signal transduction mechanisms in biological systems.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

5-Azacytidine may downregulate OR52L1 expression by causing DNA demethylation at the gene's promoter, therefore disrupting the transcriptional repression usually maintained by methylation.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$152.00
$479.00
$632.00
$1223.00
$2132.00
33
(3)

Trichostatin A could decrease OR52L1 expression by enhancing histone acetylation, which could lead to chromatin remodeling that renders the OR52L1 promoter less accessible to transcriptional machinery.

Mithramycin A

18378-89-7sc-200909
1 mg
$55.00
6
(1)

Mithramycin A has the potential to reduce OR52L1 expression by binding to G-C rich DNA sequences within the promoter region, obstructing the essential transcription factors from initiating gene transcription.

Actinomycin D

50-76-0sc-200906
sc-200906A
sc-200906B
sc-200906C
sc-200906D
5 mg
25 mg
100 mg
1 g
10 g
$74.00
$243.00
$731.00
$2572.00
$21848.00
53
(3)

Actinomycin D may inhibit OR52L1 expression by intercalating into DNA, which prevents the advancement of RNA polymerase along the OR52L1 coding region, thus hindering mRNA synthesis.

RG 108

48208-26-0sc-204235
sc-204235A
10 mg
50 mg
$131.00
$515.00
2
(1)

RG 108 could downregulate OR52L1 by inhibiting DNA methyltransferases, leading to reduced methylation levels at the OR52L1 gene promoter and subsequent transcriptional suppression.

5-Aza-2′-Deoxycytidine

2353-33-5sc-202424
sc-202424A
sc-202424B
25 mg
100 mg
250 mg
$218.00
$322.00
$426.00
7
(1)

5-Aza-2′-Deoxycytidine (Decitabine) may lead to OR52L1 downregulation by hypomethylating cytosine bases in the DNA, particularly at the gene promoter, which often silences gene activity through chromatin compaction.

Sodium Butyrate

156-54-7sc-202341
sc-202341B
sc-202341A
sc-202341C
250 mg
5 g
25 g
500 g
$31.00
$47.00
$84.00
$222.00
19
(3)

Sodium Butyrate can lead to the suppression of OR52L1 expression by increasing histone acetylation, thus creating a state of chromatin that is less favorable for the binding of transcriptional activators.

MS-275

209783-80-2sc-279455
sc-279455A
sc-279455B
1 mg
5 mg
25 mg
$24.00
$90.00
$212.00
24
(2)

MS-275 (Entinostat) may decrease OR52L1 expression levels by selectively inhibiting class I histone deacetylases, resulting in altered acetylation patterns that can silence gene transcription.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$133.00
$275.00
37
(2)

Suberoylanilide Hydroxamic Acid (Vorinostat) could suppress OR52L1 by inhibiting histone deacetylase activity, thereby increasing the acetylation of histones associated with the OR52L1 gene and altering gene expression patterns.

α-Amanitin

23109-05-9sc-202440
sc-202440A
1 mg
5 mg
$269.00
$1050.00
26
(2)

α-Amanitin may inhibit OR52L1 expression by strongly inhibiting RNA polymerase II, which is necessary for the transcription of mRNA from the OR52L1 gene, thereby reducing its overall expression.